EGFR positive

P2, N=80, Recruiting, Stanford University | Trial primary completion date: Dec 2025 --> Dec 2026

P=N/A, N=7933, Active, not recruiting, Boehringer Ingelheim | Initiation date: Jan 2026 --> Sep 2025

Recognizing its benign and self-limited nature is crucial to prevent misdiagnosis as tumor recurrence and avoid unnecessary oncologic or surgical interventions. Integration of advanced MRI techniques and multidisciplinary evaluation allows precise diagnosis and tailored management, ensuring appropriate treatment and long-term follow-up.

Liver and adrenal metastases occurred exclusively in plasma T790M-positive patients and were associated with markedly worse outcomes, consistent with a ctDNA-shedding phenotype. Bone metastasis was an adverse prognostic factor independent of plasma T790M, underscoring the combined prognostic impact of molecular and metastatic features.

No relevant statistical significance was found; the exploratory survival outcomes should be interpreted as exploratory due to high lost-to-follow up rate. These results could be useful in terms of design of future clinical trials.

Physician confidence improved (P < 0.001) and the estimated total cost savings, including direct drug costs, vein access devices, and HER2DX costs, amounted to €98 031. HER2DX impacts clinical management in stage I-III HER2-positive BC by supporting treatment adjustments, enhancing physician confidence, maintaining pCR rates, and reducing health care costs.

Palbociclib, ribociclib, and abemaciclib are approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC), in combination with aromatase inhibitors or fulvestrant...Subsequent therapies, including chemotherapy (CT), endocrine therapy (ET) with or without everolimus, and CDK4/6i-based regimens, were evaluated...These findings emphasize the variability in treatment efficacy following CDK4/6i therapy and underscore the importance of personalized treatment strategies. Further research is needed to optimize therapeutic sequences and improve patient outcomes in this setting.

The utilization of s.c. pertuzumab/trastuzumab/hyaluronidase rose from 0 to 87 doses/month, with a consequent decline in the usage of i.v. pertuzumab/trastuzumab...Reducing time toxicity and extending care to the community is pivotal to cancer patients with constrained timeframes. These findings provide valuable insights for decision making in health care policy and negotiations with drug companies to ensure s.c. formulations are affordable.

Patients were treated in first-line (1L) with osimertinib or other TKIs (non-osimertinib). This study demonstrates that real-world treatment patterns and outcomes of TKIs are comparable with those found in both clinical trials and other real-world studies. RWE studies can support clinicians in investigating the best treatment strategy and decision makers to drive new health policies.

Similarly, HER2 IHC 3+, intestinal type lesions, and better mGPS (0 or 1) are associated with longer rwPFS. However, T-DXd should not be withheld even in patients without these factors, as a median PFS of 3.42 months was observed in those with the shortest prior trastuzumab exposure.

Reduction of PDI needs careful consideration, balancing adverse events and potential impact. Confirmation in independent datasets is warranted.